A Pilot Study of Bortezomib/Dexamethasone Followed by Autologous Stem Cell Transplantation and Maintenance Bortezomib/Dexamethasone for the Initial Treatment of MIDD Associated with Multiple Myeloma and Amyloidosis

Monoclonal immunoglobulin deposition disease (MIDD — also known as Light Chain Deposition Disease, or LCDD) and amyloidosis are two rare conditions associated with abnormal plasma cells. The purpose of this study is to evaluate a treatment regimen that consists of the drugs bortezomib and dexamethasone, followed by a transplant of a patient’s own stem cells (autologous stem cell transplantation), and then another round of bortezomib and dexamethasone as maintenance therapy in patients with MIDD or amyloidosis.